Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Celldex Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Celldex Therapeutics, Inc.

CLDX

Celldex Therapeutics, Inc.

About Celldex Therapeutics, Inc.

Celldex Therapeutics is a biopharmaceutical company focused on developing antibody-based therapies targeting mast cell-driven diseases such as chronic urticaria, eosinophilic esophagitis, prurigo nodularis, and atopic dermatitis. Its portfolio includes monoclonal and bispecific antibodies designed to modulate immune pathways, with a focus on unmet medical needs. The company emphasizes research, clinical development, and strategic partnerships to advance innovative treatments for inflammatory and allergic conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Celldex Therapeutics, Inc.

1
1
Celldex Therapeutics, Inc. Celldex Therapeutics Reports 98% Revenue Decline and $78.7 Million Net Loss in Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Celldex Therapeutics, Inc. Celldex Therapeutics Reports 78% Revenue Decline and Increased Operating Losses for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Celldex Therapeutics, Inc. Celldex Therapeutics Reports $0 Revenue and $67M Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Celldex Therapeutics, Inc. Celldex Therapeutics Reports 71% Revenue Decline and $56.6 Million Net Loss in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Celldex Therapeutics, Inc. Celldex Therapeutics Reports $695K Revenue and $53.8M Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Celldex Therapeutics, Inc. Celldex Therapeutics Reports 110% Revenue Growth, Operating Losses Widen in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments